NASDAQ:JBIO Jade Biosciences Q4 2025 Earnings Results & Report $15.40 +0.06 (+0.39%) Closing price 04:00 PM EasternExtended Trading$15.44 +0.04 (+0.26%) As of 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Jade Biosciences beat analyst earnings expectations in its Q4 2025 results, released March 6, 2026. The company reported EPS of -$0.11 versus the -$0.45 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 6, 2026TimeAfter Market ClosesConference Call7:00 AM ET Jade Biosciences EPS ResultsActual EPS-$0.11Consensus EPS -$0.45Beat/MissBeat by +$0.34One Year Ago EPSN/AEPS Beat Rate3 of last 6 quartersJade Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Jade Biosciences Q4 2025 Earnings FAQ Did Jade Biosciences beat earnings estimates for Q4 2025? Jade Biosciences (NASDAQ:JBIO) reported earnings of -$0.11 per share for Q4 2025, beating the consensus estimate of -$0.45. The report was announced on Friday, March 6, 2026. Jade Biosciences Earnings HeadlinesJade Biosciences (JBIO) Stock Price Target 2026November 17 at 12:34 PM | benzinga.comJade Biosciences (NASDAQ:JBIO) Upgraded at Wall Street ZenNovember 17 at 6:46 AM | americanbankingnews.comUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washington is set to take place by November 30th. He believes it could create one of the most chaotic environments in America's history. He predicts those who understand what's happening could do very well over the next 12-18 months, while others may face steep losses. Rickards outlines the five steps he recommends.November 17 at 1:00 AM | Paradigm Press (Ad)Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Now Rated "Moderate Buy" by Wall Street AnalystsNovember 17 at 1:32 AM | americanbankingnews.comJade Biosciences, Inc. (JBIO) Presents at UBS Global Biopharma Conference 2026 TranscriptNovember 16 at 3:32 PM | seekingalpha.comJade Biosciences, Inc. (JBIO) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks TranscriptNovember 16 at 12:22 PM | seekingalpha.comSee More Jade Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Jade Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jade Biosciences and other key companies, straight to your email. Email Address About Jade BiosciencesJade Biosciences (NASDAQ:JBIO) is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease. The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys. Jade’s pipeline is focused on potential therapies for autoimmune conditions. The company’s work is at the drug-development stage, and its programs are intended to address diseases with significant unmet treatment needs.View Jade Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.